Foretinib
Encyclopedia
Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis
and is under development by GlaxoSmithKline
. It is currently in Phase II clinical trials.
Foretinib is an inhibitor
of the kinase
enzymes c-Met
and vascular endothelial growth factor receptor 2 (VEGFR-2).
Exelixis
Exelixis is a genomics-based drug discovery company located in South San Francisco, Ca. It works on the development of anti-cancer therapies. Exelixis has several compounds in various stages of FDA approval including :...
and is under development by GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline plc is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom...
. It is currently in Phase II clinical trials.
Foretinib is an inhibitor
Enzyme inhibitor
An enzyme inhibitor is a molecule that binds to enzymes and decreases their activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. They are also used as herbicides and pesticides...
of the kinase
Kinase
In chemistry and biochemistry, a kinase is a type of enzyme that transfers phosphate groups from high-energy donor molecules, such as ATP, to specific substrates, a process referred to as phosphorylation. Kinases are part of the larger family of phosphotransferases...
enzymes c-Met
C-MET
c-Met is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor . The hepatocyte growth factor receptor protein possesses tyrosine-kinase activity...
and vascular endothelial growth factor receptor 2 (VEGFR-2).